Eupraxia Pharmaceuticals Inc (EPRX) Stock Price, Quote & News

Company Profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and E...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 590 3968

Website: www.eupraxiapharma.com

Address:

2067 Cadboro Bay Road, Suite 201, Victoria, Canada

laaarsas May. 7 at 5:07 PM

$EPRX I am so sorry I was mistaken there is no DSQ data in phase 2a it comes in phase 2b! Stay positive!

0 · Reply

jheerdink May. 7 at 4:43 PM

$EPRX https://vistapglobal.com/from-weekly-jabs-to-yearly-scopes-why-eupraxias-ep-104gi-might-have-sanofi-checking-its-calendar-eprx-sny-xbi/ $SNY

0 · Reply

laaarsas May. 6 at 8:48 PM

$EPRX They provide a lot of data to make up the pig instead of just giving us what matters: the DSQ data. They hide it. Why? Why would you hide something like that from the investors? Is it because you administer something in the esophageal mucosa, and that itself could cause symptoms, even if you achieve histological remission? Email them! Ask them! Demand answers!!

0 · Reply

laaarsas May. 5 at 3:01 PM

$EPRX Where is the DSQ data??? Email them! Ask them! It’s fucking plain and simple omission!! Put pressure on them!!

1 · Reply

BillionerOfKing May. 5 at 12:49 AM

$EPRX Current Stock Price: $7.47

0 · Reply

BioTuesdays May. 4 at 2:36 PM

$EPRX has announced the appointment of Jeymi Tambiah, MB ChB, FRCS, MS, FAPCR, FFPM, as chief medical officer (CMO), and the retirement of the current CMO, Dr. Mark Kowalski. https://biotuesdays.com/2026/05/04/eupraxia-appoints-dr-jeymi-tambiah-as-cmo/

0 · Reply

Quantumup May. 4 at 10:35 AM

Piper Sandler🏁 $TRAX.X and said: We are initiating coverage on First Tracks Biotherapeutics, Inc. (TRAX) with an OW rating and $54 PT given its differentiated pipeline across ANB033 (CD122 antagonist), rosnilimab (pathogenic T-cell depleter), and ANB101 (BDCA2 modulator). $ANAB ENTO FBRX TAK SNY TEVA AZN BMY $EPRX PHAT ABBV GILD REGN PFE LLY Here's what else Piper Sandler had to say in its note to investors: https://x.com/Quantumup1/status/2051248806482612476?s=20

1 · Reply

jheerdink Apr. 30 at 3:06 PM

$EPRX "The company is heading to Digestive Disease Week, one of the premier GI conferences, to present four abstracts featuring its lead asset EP‑104GI in eosinophilic esophagitis. The presentations will cover 36‑week data from the Phase 1b/2 RESOLVE trial, including histology, endoscopy and symptom durability measures." https://vistapglobal.com/healthcares-quiet-rally-incyte-pfizer-eupraxia-put-some-spring-in-wall-streets-step-eprx-incy-pfe-xbi/

0 · Reply

SuperGreenToday Apr. 29 at 3:00 AM

$EPRX

0 · Reply

jheerdink Apr. 24 at 6:56 PM

$EPRX https://vistapglobal.com/not-just-chips-and-giggles-pairing-high-flying-tech-with-serious-healthcare-winners-ai-amd-cah-cvs-eprx-modd-jnj-nvda-podd-tndm/

0 · Reply

Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year

Tue, 12 May 2026 17:00:00 -0400 - 1 day ago

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Wed, 06 May 2026 07:00:00 -0400 - 7 days ago

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Tue, 05 May 2026 07:00:00 -0400 - 8 days ago

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

2026-05-01T21:10:18.000Z - 12 days ago

Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as Chief Medical Officer

Fri, 01 May 2026 17:05:00 -0400 - 12 days ago

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Wed, 22 Apr 2026 07:00:00 -0400 - 21 days ago

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

2026-04-21T12:37:50.000Z - 22 days ago

Eupraxia reports 9-month tissue symptom data from Phase 1b/2a Resolve trial

Mon, 23 Mar 2026 13:59:37 -0400 - 7 weeks ago

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

2026-03-23T11:01:07.000Z - 7 weeks ago

Eupraxia Pharmaceuticals initiated with an Outperform at William Blair

2026-03-17T11:12:02.000Z - 2 months ago

Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease

2026-03-17T10:10:56.000Z - 2 months ago

Eupraxia price target lowered to $11 from $12 at H.C. Wainwright

Thu, 12 Mar 2026 21:03:00 -0400 - 2 months ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Feb 20, 2026, 3:10 PM EST - 2 months ago

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

2026-02-19T11:10:34.000Z - 2 months ago

Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00

Feb 19, 2026, 2:18 AM EST - 2 months ago

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

2026-02-18T21:11:55.000Z - 3 months ago

Eupraxia Pharmaceuticals announces common shares offering, no amount given

Feb 18, 2026, 4:01 PM EST - 3 months ago

Eupraxia Pharmaceuticals Announces Proposed Public Offering

2026-02-02T18:55:09.000Z - 3 months ago

Eupraxia Pharmaceuticals management to meet with Cantor

2026-01-15T12:35:51.000Z - 4 months ago

Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald

2026-01-08T12:43:15.000Z - 4 months ago

Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial

Jan 8, 2026, 7:34 AM EST - 4 months ago

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

2025-11-13T22:15:40.000Z - 6 months ago

Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in follow-up esophagitis data

Nov 13, 2025, 5:00 PM EST - 6 months ago

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

Nov 4, 2025, 4:39 PM EST - 6 months ago

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

2025-10-27T18:45:22.000Z - 7 months ago

Eupraxia Pharmaceuticals management to meet virtually with Craig-Hallum

2025-09-29T21:05:17.000Z - 8 months ago

Eupraxia announces ‘positive’ data from highest-dose cohort in RESOLVE trial

Sep 29, 2025, 5:00 PM EDT - 8 months ago

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Sep 24, 2025, 8:54 AM EDT - 8 months ago

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

2025-09-23T10:20:28.000Z - 8 months ago

Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50

Sep 22, 2025, 10:42 PM EDT - 8 months ago

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

2025-09-22T20:10:38.000Z - 8 months ago

Eupraxia Pharmaceuticals announces common shares offering, no amount given

Sep 22, 2025, 4:01 PM EDT - 8 months ago

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

2025-09-02T12:35:08.000Z - 9 months ago

Eupraxia Pharmaceuticals announces data from RESOLVE trial in EoE

2025-08-20T10:30:24.000Z - 9 months ago

Celldex data supports positive Eupraxia thesis, says H.C. Wainwright

CLDX

Aug 12, 2025, 4:25 PM EDT - 9 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-07-24T10:16:06.000Z - 10 months ago

Eupraxia Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald

Jul 22, 2025, 5:17 PM EDT - 10 months ago

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Jul 8, 2025, 7:00 AM EDT - 11 months ago

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Jun 2, 2025, 6:30 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

May 7, 2025, 2:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

May 6, 2025, 6:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Apr 24, 2025, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Mar 20, 2025, 5:31 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Feb 25, 2025, 7:00 AM EST - 1 year ago

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Feb 18, 2025, 7:00 AM EST - 1 year ago

Eupraxia Pharmaceuticals Announces CFO Succession

Nov 20, 2024, 7:00 AM EST - 1 year ago

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Nov 14, 2024, 5:00 PM EST - 1 year ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Nov 13, 2024, 5:00 PM EST - 1 year ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Nov 12, 2024, 5:56 PM EST - 1 year ago

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Nov 7, 2024, 5:00 PM EST - 1 year ago

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 7:36 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Oct 2, 2024, 5:01 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Sep 19, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

Jul 8, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Jul 3, 2024, 5:00 PM EDT - 2 years ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

May 23, 2024, 5:00 PM EDT - 2 years ago

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 22, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

May 21, 2024, 5:00 PM EDT - 2 years ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 14, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

May 8, 2024, 5:03 PM EDT - 2 years ago

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

laaarsas May. 7 at 5:07 PM

$EPRX I am so sorry I was mistaken there is no DSQ data in phase 2a it comes in phase 2b! Stay positive!

0 · Reply

jheerdink May. 7 at 4:43 PM

$EPRX https://vistapglobal.com/from-weekly-jabs-to-yearly-scopes-why-eupraxias-ep-104gi-might-have-sanofi-checking-its-calendar-eprx-sny-xbi/ $SNY

0 · Reply

laaarsas May. 6 at 8:48 PM

0 · Reply

laaarsas May. 5 at 3:01 PM

$EPRX Where is the DSQ data??? Email them! Ask them! It’s fucking plain and simple omission!! Put pressure on them!!

1 · Reply

BillionerOfKing May. 5 at 12:49 AM

$EPRX Current Stock Price: $7.47

0 · Reply

BioTuesdays May. 4 at 2:36 PM

0 · Reply

Quantumup May. 4 at 10:35 AM

1 · Reply

jheerdink Apr. 30 at 3:06 PM

0 · Reply

SuperGreenToday Apr. 29 at 3:00 AM

$EPRX

0 · Reply

jheerdink Apr. 24 at 6:56 PM

$EPRX https://vistapglobal.com/not-just-chips-and-giggles-pairing-high-flying-tech-with-serious-healthcare-winners-ai-amd-cah-cvs-eprx-modd-jnj-nvda-podd-tndm/

0 · Reply

laaarsas Apr. 21 at 3:12 PM

$EPRX Why have no DSQ been reported? It’s very important endpoint. Only SDI reported. Selective data reporting is HUGE red flag. Where is DSQ data?

0 · Reply

laaarsas Apr. 21 at 1:43 PM

$EPRX Dogshit PR. Where is the more granular EoEHHS data? From more cohorts? For baseline, w12 and w36?

0 · Reply

jheerdink Apr. 21 at 1:32 PM

$EPRX https://investors.eupraxiapharma.com/news-releases/news-release-details/eupraxia-pharmaceuticals-reports-positive-nine-month-tissue

0 · Reply

laaarsas Apr. 16 at 12:29 PM

$EPRX ofc no one cares money is not that important I guess

0 · Reply

laaarsas Apr. 16 at 12:14 PM

$EPRX when will they release more data from all cohorts?? Baseline , w12 and w36??? What are they hiding??

0 · Reply

laaarsas Apr. 16 at 6:22 AM

$EPRX why don’t they disclose the effect size for all cohorts???? Why don’t they disclose basline, w12 and w36 for alla cohorts?? Wtf fkn scammers

1 · Reply

Moneybags789 Apr. 15 at 8:31 PM

$EPRX 👀👀👀👀

0 · Reply

laaarsas Apr. 15 at 5:33 AM

$EPRX what effect size for EOEHHS (added effect after subtracting placebo response) do you think the market demands to call this a clear win?

0 · Reply

laaarsas Apr. 14 at 10:07 PM

$EPRX Fkn scammers where is the cohort 7 and 8 data???? and 36w data from cohort 6??? Piece of shits

0 · Reply

laaarsas Apr. 14 at 9:50 PM

$EPRX Where is the detailed data for cohort 7 and 8?

1 · Reply

laaarsas Apr. 14 at 9:17 PM

$EPRX So far I'm getting homerun vibes from this one. What the catch? Please throw all negatives/risks at me

0 · Reply

laaarsas Apr. 14 at 6:22 PM

$EPRX yo

0 · Reply

Market Cap	448.42M
Revenue (ttm)	0.00
Net Income (ttm)	-38.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	85,219
Avg Vol	193,898
Day's Range	N/A - N/A
Shares Out	60.43M
Stochastic %K	52%
Beta	1.19
Analysts	Strong Sell
Price Target	$15.19